Epigenomics AG (DB: ECX)
Health Care · Biotechnology · DE
€0.91
-3.19% today · +7.1% 1Y
Epigenomics AG (DB: ECX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $931.65K and employs 3 people.
Over the last twelve months the share price has gained 7.1%, trading between 0.84 and 1.59.
Tweenvest scores Epigenomics AG across four factors: quality 23/100, value 61/100. Its strongest factor is value.
ECX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $931.65K
- Revenue (TTM)
- $28.18K
- P/E
- —
- EPS
- -0.36
- Dividend yield
- —
- Beta (5Y)
- 0.87
- 52-week high
- €1.59
- 52-week low
- €0.84
- Avg volume (3M)
- —
- Shares outstanding
- 876.98K
- Employees
- 3
- Next earnings
- —
About Epigenomics AG
Epigenomics AG currently has no significant business activities. Historically, the firm concentrated its efforts on developing liquid biopsy methods for the early identification of cancer. The company was established in 1998 and is based in Heidelberg, Germany.
- Founded
- 1998
- Listed since
- Jul 19, 2004
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.